Table 1.
Patient characteristics (n=243).
| Variable | N | % |
|---|---|---|
| Sex | ||
| Male | 135 | 56% |
| Female | 108 | 44% |
| Age (years) | ||
| Median, range | 59 | 22-81 |
| Diagnosis | ||
| AML | 107 | 44% |
| MDS | 37 | 15% |
| ALL | 23 | 10% |
| MPN | 38 | 16% |
| NHL | 32 | 13% |
| other | 6 | 2% |
| Donor type | ||
| SIB | 53 | 22% |
| MUD | 160 | 66% |
| MMUD | 24 | 10% |
| HAPLO | 6 | 2% |
| Conditioning Regime | ||
| RIC | 129 | 53% |
| MAC | 114 | 47% |
| Vaccination | ||
| BNT162b2 | 201 | 83% |
| mRNA-1273 | 5 | 2% |
| ChAdOx1-S | 25 | 10% |
| JNJ-78436735 | 1 | 0,4% |
| Mixed Vaccination | 11 | 4,6% |
| Antibody test (SARS-CoV2-Spike glycoprotein) | ||
| Roche EIA | 158 | 65% |
| EUROIMMUN ELISA | 85 | 35% |
| Time from transplant to first vaccination | ||
| median, range (days) | 750 | 40-10.566 |
| Time from second/third vaccination to test | ||
| second vac. (median, range (days)) | 42 | 5-159 |
| third vac. (median, range (days)) | 41 | 6-151 |
AML, Acute myeloid leukemia; MDS, Myelodysplastic Syndrome; ALL, Acute lymphatic leukemia; MPN, Myeloproliferative Neoplasia; NHL, Non-Hodgkin Lymphoma; SIB, Sibling Donor; MUD, Matched unrelated Donor; MMUD, Mismatched unrelated Donor; HAPLO, Haploidentical Donor; RIC, Reduced intensity conditioning; MAC, Myeloablative conditioning; EIA, Enzymimmunoassay; ELISA, Enzyme-Linked Immunosorbent Assay; Vac, Vaccination.